These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression. Ichikawa A; Arakawa F; Kiyasu J; Sato K; Miyoshi H; Niino D; Kimura Y; Takeuchi M; Yoshida M; Ishibashi Y; Nakashima S; Sugita Y; Miura O; Ohshima K Eur J Haematol; 2013 Jul; 91(1):20-8. PubMed ID: 23560463 [TBL] [Abstract][Full Text] [Related]
8. Prognostic factors of methotrexate-associated lymphoproliferative disorders associated with rheumatoid arthritis and plausible application of biological agents. Katsuyama T; Sada KE; Yan M; Zeggar S; Hiramatsu S; Miyawaki Y; Ohashi K; Morishita M; Watanabe H; Katsuyama E; Takano-Narazaki M; Toyota-Tatebe N; Sunahori-Watanabe K; Kawabata T; Miyake K; Kiguchi T; Wada J Mod Rheumatol; 2017 Sep; 27(5):773-777. PubMed ID: 27846761 [TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics and incidence of methotrexate-related lymphoproliferative disorders of patients with rheumatoid arthritis. Yoshida Y; Takahashi Y; Yamashita H; Kano T; Kaneko H; Mimori A Mod Rheumatol; 2014 Sep; 24(5):763-5. PubMed ID: 24498893 [TBL] [Abstract][Full Text] [Related]
10. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. Hoshida Y; Xu JX; Fujita S; Nakamichi I; Ikeda J; Tomita Y; Nakatsuka S; Tamaru J; Iizuka A; Takeuchi T; Aozasa K J Rheumatol; 2007 Feb; 34(2):322-31. PubMed ID: 17117491 [TBL] [Abstract][Full Text] [Related]
11. Association of methotrexate use and lymphoproliferative disorder in patients with rheumatoid arthritis: Results from a Japanese multi-institutional retrospective study. Honda S; Sakai R; Inoue E; Majima M; Konda N; Takada H; Kihara M; Yajima N; Nanki T; Yamamoto K; Takeuchi T; Harigai M Mod Rheumatol; 2022 Jan; 32(1):16-23. PubMed ID: 33428479 [TBL] [Abstract][Full Text] [Related]
12. A case of rheumatoid arthritis with methotrexate related lymphoproliferative diseases of the knee. Abe A; Wakaki K; Ishikawa H; Ito S; Murasawa A Mod Rheumatol; 2018 May; 28(3):550-554. PubMed ID: 26558294 [TBL] [Abstract][Full Text] [Related]
13. Characteristics and risk factors of lymphoproliferative disorders among patients with rheumatoid arthritis concurrently treated with methotrexate: a nested case-control study of the IORRA cohort. Shimizu Y; Nakajima A; Inoue E; Shidara K; Sugimoto N; Seto Y; Tanaka E; Momohara S; Taniguchi A; Yamanaka H Clin Rheumatol; 2017 Jun; 36(6):1237-1245. PubMed ID: 28455827 [TBL] [Abstract][Full Text] [Related]
14. PD-L1 expression is associated with the spontaneous regression of patients with methotrexate-associated lymphoproliferative disorders. Gion Y; Doi M; Nishimura Y; Ikeda T; Filiz Nishimura M; Sakamoto M; Egusa Y; Nishikori A; Fujita A; Iwaki N; Nakamura N; Yoshino T; Sato Y Cancer Med; 2022 Jan; 11(2):417-432. PubMed ID: 34842351 [TBL] [Abstract][Full Text] [Related]
15. Distinct patterns of lymphocyte count transition in lymphoproliferative disorder in patients with rheumatoid arthritis treated with methotrexate. Saito S; Kaneko Y; Yamaoka K; Tokuhira M; Takeuchi T Rheumatology (Oxford); 2017 Jun; 56(6):940-946. PubMed ID: 28165538 [TBL] [Abstract][Full Text] [Related]